Get started
RESMED INCRESMED INCRESMED INC

RESMED INC

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

RMD chart


Full chart

RMD upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪691.09 B‬ MXN
Dividend yield (indicated)
0.92%
Price to earnings Ratio (TTM)
31.67
Basic EPS (TTM)
149.22 MXN
Net income (FY)
‪18.73 B‬ MXN
Revenue (FY)
‪85.94 B‬ MXN
Shares float
‪145.64 M‬
Beta (1Y)
0.90

Employees


Employees (FY)
‪9.98 K‬
Change (1Y)
−160 −1.58%
Revenue / Employee (1Y)
‪8.61 M‬ MXN
Net income / Employee (1Y)
‪1.88 M‬ MXN

About ResMed Inc.


Sector
Health Technology
Industry
Medical Specialties
CEO
Michael J. Farrell
Website
resmed.com
Headquarters
San Diego
Founded
1989
FIGI
BBG00PGH15M2
ResMed, Inc. engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases. The firm operates through the Sleep and Respiratory Care and Software as a Service segments. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry. The Software as a Service segment provides business management software as a service to out-of-hospital health providers. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

RMD news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of RMD is 4,905.00 MXN — it has increased by 1.64% in the past 24 hours. Watch RESMED INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BMV exchange RESMED INC stocks are traded under the ticker RMD.
RMD stock has risen by 1.64% compared to the previous week, the month change is a 2.62% rise, over the last year RESMED INC has showed a 83.61% increase.
We've gathered analysts' opinions on RESMED INC future price: according to them, RMD price has a max estimate of 5,822.59 MXN and a min estimate of 3,827.87 MXN. Watch RMD chart and read a more detailed RESMED INC stock forecast: see what analysts think of RESMED INC and suggest that you do with its stocks.
RMD reached its all-time high on Dec 14, 2021 with the price of 5,396.94 MXN, and its all-time low was 2,306.60 MXN and was reached on Jun 21, 2019. View more price dynamics on RMD chart.
See other stocks reaching their highest and lowest prices.
RMD stock is 1.61% volatile and has beta coefficient of 0.90. Track RESMED INC stock price on the chart and check out the list of the most volatile stocks — is RESMED INC there?
Today RESMED INC has the market capitalization of ‪708.08 B‬, it has decreased by −1.82% over the last week.
Yes, you can track RESMED INC financials in yearly and quarterly reports right on TradingView.
RESMED INC is going to release the next earnings report on Jan 23, 2025. Keep track of upcoming events with our Earnings Calendar.
RMD earnings for the last quarter are 43.35 MXN per share, whereas the estimation was 40.47 MXN resulting in a 7.10% surprise. The estimated earnings for the next quarter are 47.22 MXN per share. See more details about RESMED INC earnings.
RESMED INC revenue for the last quarter amounts to ‪24.13 B‬ MXN, despite the estimated figure of ‪23.35 B‬ MXN. In the next quarter, revenue is expected to reach ‪25.83 B‬ MXN.
RMD net income for the last quarter is ‪6.13 B‬ MXN, while the quarter before that showed ‪5.36 B‬ MXN of net income which accounts for 14.45% change. Track more RESMED INC financial stats to get the full picture.
Yes, RMD dividends are paid quarterly. The last dividend per share was 10.50 MXN. As of today, Dividend Yield (TTM)% is 0.85%. Tracking RESMED INC dividends might help you take more informed decisions.
RESMED INC dividend yield was 1.00% in 2024, and payout ratio reached 27.75%. The year before the numbers were 0.81% and 28.91% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Dec 22, 2024, the company has ‪9.98 K‬ employees. See our rating of the largest employees — is RESMED INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. RESMED INC EBITDA is ‪33.47 B‬ MXN, and current EBITDA margin is 34.16%. See more stats in RESMED INC financial statements.
Like other stocks, RMD shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade RESMED INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So RESMED INC technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating RESMED INC stock shows the buy signal. See more of RESMED INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.